Generic drug companies are standing on the cusp of a once-in-a-lifetime opportunity.
In the next five years, a total of $290 billion in prescription drug sales are expected...(read more
On Monday, Pfizer Inc. (NYSE:PFE) announced plans to purchase an attention-deficit/hyperactivity (ADHD) disorder drug developer, NextWave Pharmaceuticals. The deal could carry a $700...(read more
Pfizer Inc. (PFE) recently announced European Commission approval of its renal cell cancer drug, Inlyta (axitinib). Inlyta gained approval from the EC for use in...(read more